osimertinib

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

osimertinib
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 2, 2024, 09:38 | Insight
Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib
Antonio Passaro, shared a post on X: "EMA approves amivantamab in combination with chemo for…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 29, 2024, 16:56 | Insight
Stephen Liu: Overview of outcomes with 1L osimertinib
Stephen Liu shared a post on X about a recent paper by Kageaki Watanabe et…
Aug 29, 2024, 16:15 | Drugs
Antonio Passaro: European Commission approves amivantamab
Antonio Passaro shared on LinkedIn: "I'm proud to announce that, yesterday August 27, the European…
Aug 27, 2024, 22:13 | Insight
Stephen Liu: Final anaysis of WJOG9717L
Stephen Liu shared a post on X: “Final anaysis of WJOG9717L (phase II osimertinib +/-…
Aug 27, 2024, 21:52 | Blog
David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA
David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post…
Aug 26, 2024, 21:24 | Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 14, 2024, 13:49 | Insight
Amol Akhade: New and exciting data coming up at WLCC 24
Amol Akhade shared on X about recent papers: "What's new and exciting data coming up…
Aug 8, 2024, 13:30 | Blog
MARIPOSA for EGFR-mutant lung cancer - EGFR Positive UK
EGFR Positive UK shared a post on X: ''Interesting discussion re future of osimertinib following…
Aug 6, 2024, 06:07 | Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Jul 27, 2024, 10:23 | Blog
C S Pramesh: Welcome move to exempt some important cancer medicines from customs duty
C S Pramesh, Director of the Tata Memorial Hospital and the Professor and Head of…
Jul 24, 2024, 13:40 | Blog
Collin Blakely: Neoadjuvant Osimertinib for the Treatment of Non–Small Cell Lung Cancer
Collin Blakely, Associate Professor of Thoracic Medical Oncology and Clinical Scientist at UCSF, shared a…
Jul 22, 2024, 02:59 | Blog
CtDNA Analysis on Osimertinib in FLAURA and AURA3 trials
Jarushka Naidoo shared a post on X about an article by Jhanelle Gray et al. titled…
Jul 21, 2024, 13:36 | Blog
Rami Manochakian: Neoadjuvant osimertinib in stage I-IIIA EGFRm NSCLC did not meet primary endpoint
Rami Manochakian shared a post on X: ''Hot off the press. Neoadjuvant Osimertinib for the…
Jul 19, 2024, 22:55 | Blog
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X: "What after Osimertinib…
Jul 12, 2024, 23:07 | Insight
Osimertinib could change the standard of care for EGFR-mutant NSCLC
Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X: "Osimertinib could change…
Jul 2, 2024, 04:16 | Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 26, 2024, 12:05 | Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 21, 2024, 09:39 | Insight
Stephanie Saw: Real-world evidence of adding pemetrexed-platinum chemotherapy upon osimertinib progression
Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared on X/Twitter: "Just out in…
Jun 10, 2024, 11:09 | Insight
Phase II BLOSSOM Trial Osimertinib in LMD from EGFR+ NSCLC by Sehhoon Park et al.
Jarushka Naidoo shared a post on X: "Phase II BLOSSOM Trial Osimertinib in LMD (leptomeningeal…
Jun 10, 2024, 00:53 | Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
Jun 4, 2024, 04:18 | Blog
Narjust Florez: So lucky to call Dr. Lecia Sequist my mentor
Narjust Florez shared a post on X: "So lucky to call this amazing physician my…
May 29, 2024, 12:03 | Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X:  "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 26, 2024, 06:31 | Insight
Vivek Subbiah: Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma
Vivek Subbiah shared a post on X/Twitter: "Impressive response to dabrafenib, trametinib, and osimertinib in a…
May 25, 2024, 14:28 | Blog
Studies conducted by Dana-Farber at this year’s AACR Annual Meeting
Dana-Farber Cancer Institute shared on LinkedIn: "Numerous studies conducted by Dana-Farber researchers show promising results for…
May 23, 2024, 07:56 | Blog
Chinmay Jani: Let's explore EGFR Exon 20 Insertion NSCLC with a twist of Miami flair!
Chinmay Jani, Clinical Fellow, Hematology & Oncology at University of Miami, made the following post…
Apr 23, 2024, 18:57 | Insight
New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature
Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…
Apr 13, 2024, 09:17 | Societies
30 Posts Not To Miss From AACR24!
The AACR Annual Meeting 2024 was held from April 5th to 10th in San Diego,…
Apr 12, 2024, 11:46 | Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Apr 4, 2024, 13:34 | Drugs
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…
Feb 28, 2024, 18:42 | Drugs
Amalya Sargsyan: Excitement around osimertinib in the NSCLC community
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn: "Huge…
Feb 23, 2024, 14:31 | Blog
Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least
Rasika Bombatkar, Citizen Scientist at LUNGevity Foundation, cancer patient and advocate, shared on X: "AstraZeneca,…
Feb 17, 2024, 15:57 | Insight
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: "Hot off…
Feb 7, 2024, 12:46 | Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Feb 5, 2024, 11:27 | Insight
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Jan 16, 2024, 05:48 | Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Nov 28, 2023, 18:00 | Drugs
Stephen V Liu: Report on real world efficacy and safety of amivantamab including off label use
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at the Lombardi Comprehensive Cancer…
Nov 12, 2023, 17:56 | Drugs
David Planchard: Thank you to the patients who actively participated in this research
David Planchard, Professor at the University Paris Saclay, posted on X/Twitter. "Proud to lead this…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
Oct 17, 2023, 16:44 | Insight
Stephen V Liu reflected on the OCEAN study published in the Journal of Thoracic Oncology
Quoting Stephen V Liu, Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown…
Jul 23, 2023, 17:05 | Blog
ASCO expert panel chaired by Navneet Singh and Megan Daly has published an update on management of stage III NSCLC based on the ADAURA and KEYNOTE-671 trials - Navneet Singh
All: 47 Posts: 1 - 100
Special Coverage